187:@0.890196:0.957873:0.914454:0.957873:0.914454:0.938882:0.890196:0.938882:0.007450:0.008218:0.008591
REFERENCES:@0.789358:0.066557:0.882352:0.066557:0.882352:0.045634:0.789358:0.045634:0.010295:0.008537:0.008058:0.008537:0.010295:0.008537:0.010706:0.010089:0.008398:0.009542
57.  Abbosh, C. :@0.147059:0.119718:0.273395:0.119718:0.273395:0.101197:0.147059:0.101197:0.009483:0.009483:0.004088:0.003735:0.010563:0.012908:0.009940:0.010231:0.009961:0.006869:0.010417:0.004088:0.003403:0.013343:0.004088:0.003735
et al.:@0.273071:0.119718:0.307871:0.119718:0.307871:0.101006:0.273071:0.101006:0.007346:0.005727:0.003486:0.009048:0.004607:0.004586
 Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Na-:@0.307867:0.119718:0.882353:0.119718:0.882353:0.101197:0.307867:0.101197:0.003403:0.010749:0.010065:0.008902:0.004711:0.010044:0.008778:0.008218:0.010542:0.008301:0.005852:0.005043:0.008176:0.003403:0.008280:0.005852:0.014339:0.014007:0.013572:0.003403:0.008259:0.010625:0.008550:0.004711:0.008840:0.006910:0.005105:0.006973:0.003403:0.010293:0.008299:0.010067:0.005043:0.008278:0.005852:0.006973:0.003403:0.008444:0.008259:0.006912:0.004711:0.008840:0.006848:0.006827:0.005954:0.008363:0.008778:0.008218:0.003403:0.004462:0.010376:0.010417:0.008965:0.003403:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.003403:0.008487:0.008757:0.009940:0.004462:0.010065:0.005852:0.005043:0.009857:0.010687:0.004088:0.003403:0.014132:0.008489:0.006848
ture 545, 446–451 (2017).:@0.184412:0.140297:0.381386:0.140297:0.381386:0.121776:0.184412:0.121776:0.005603:0.010376:0.006765:0.008218:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
58.  Parkinson, C. A. :@0.147059:0.160875:0.313030:0.160875:0.313030:0.142355:0.147059:0.142355:0.009483:0.009483:0.004088:0.003735:0.010563:0.010376:0.008259:0.006910:0.009733:0.005105:0.010563:0.007159:0.009857:0.010687:0.004088:0.003528:0.013343:0.004088:0.003528:0.013572:0.004088:0.003735
et al.:@0.312844:0.160875:0.347769:0.160875:0.347769:0.142164:0.312844:0.142164:0.007346:0.005727:0.003611:0.009048:0.004607:0.004586
 Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA :@0.347770:0.160875:0.886026:0.160875:0.886026:0.142355:0.347770:0.142355:0.003528:0.011061:0.009172:0.010148:0.004711:0.009857:0.007180:0.008010:0.005644:0.009857:0.007637:0.008840:0.003528:0.013572:0.010625:0.008550:0.004711:0.008840:0.006910:0.005105:0.006973:0.003528:0.009857:0.005644:0.003528:0.012140:0.011061:0.009483:0.009483:0.003528:0.016954:0.010065:0.005956:0.008010:0.005852:0.005043:0.009857:0.010563:0.006973:0.003528:0.005105:0.010687:0.003528:0.013281:0.005105:0.006765:0.008280:0.010500:0.004939:0.008010:0.005852:0.005105:0.010417:0.008965:0.003528:0.009919:0.010376:0.015896:0.009836:0.010376:0.007097:0.003528:0.014339:0.014007:0.013572:0.003735
as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovari-:@0.184412:0.181454:0.882353:0.181454:0.882353:0.162933:0.184412:0.162933:0.008446:0.006973:0.003600:0.011351:0.005043:0.009857:0.015979:0.008259:0.006910:0.009338:0.008218:0.006931:0.006973:0.003600:0.009857:0.005644:0.003600:0.010210:0.006765:0.008444:0.008010:0.005852:0.015896:0.008218:0.010355:0.005852:0.003600:0.012451:0.008218:0.006827:0.010459:0.009857:0.010563:0.007159:0.008218:0.003600:0.005478:0.009857:0.007097:0.003598:0.010376:0.008010:0.005852:0.005043:0.008218:0.010355:0.005852:0.006973:0.003600:0.013385:0.004794:0.006018:0.010417:0.003600:0.012451:0.008133:0.004939:0.008010:0.010168:0.007159:0.008280:0.010355:0.003600:0.014983:0.005105:0.009025:0.010417:0.006848:0.014070:0.007180:0.008446:0.010293:0.008218:0.003600:0.009629:0.008218:0.006765:0.009836:0.010376:0.006973:0.003600:0.015354:0.008944:0.008261:0.007097:0.005105:0.006848
an Carcinoma: A Retrospective Study. PLoS Med. 13, e1002198 (2016).:@0.184412:0.202033:0.725487:0.202033:0.725487:0.183512:0.184412:0.183512:0.008259:0.010687:0.003735:0.013613:0.008259:0.006765:0.008176:0.005105:0.010542:0.009857:0.015979:0.008446:0.004088:0.003735:0.013572:0.003735:0.012449:0.008303:0.005852:0.006765:0.009959:0.006829:0.010457:0.008280:0.008280:0.005852:0.005043:0.008757:0.008218:0.003735:0.008902:0.005603:0.010314:0.010293:0.007263:0.004088:0.003735:0.010604:0.010749:0.010044:0.009193:0.003735:0.017245:0.008280:0.010106:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.008218:0.009483:0.009483:0.009483:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
59.  Bettegowda, C. :@0.147059:0.222612:0.305788:0.222612:0.305788:0.204091:0.147059:0.204091:0.009483:0.009483:0.004088:0.003735:0.010563:0.011891:0.008301:0.005603:0.005644:0.008218:0.008778:0.009878:0.013198:0.010521:0.008446:0.004088:0.005644:0.013343:0.004088:0.003735
et al.:@0.307684:0.222612:0.344767:0.222612:0.344767:0.203900:0.307684:0.203900:0.007346:0.005727:0.005769:0.009048:0.004607:0.004586
 Detection of circulating tumor DNA in early- and late-stage human :@0.344761:0.222612:0.886150:0.222612:0.886150:0.204091:0.344761:0.204091:0.005644:0.014754:0.008301:0.005644:0.008280:0.008280:0.005852:0.005043:0.009857:0.010687:0.005644:0.009857:0.005644:0.005644:0.008176:0.005105:0.006765:0.008280:0.010500:0.004939:0.008010:0.005852:0.005105:0.010417:0.008965:0.005644:0.005603:0.010376:0.015896:0.009857:0.007097:0.005644:0.014339:0.014007:0.013572:0.005644:0.005105:0.010687:0.005644:0.008446:0.008259:0.006910:0.004711:0.008840:0.006848:0.005644:0.008259:0.010542:0.010355:0.005644:0.004939:0.008010:0.005644:0.008218:0.006848:0.006827:0.005956:0.008363:0.008778:0.008218:0.005644:0.010085:0.010376:0.015979:0.008259:0.010687:0.003735
malignancies. Sci. Transl. Med. 6, 224ra24 (2014).:@0.184412:0.243190:0.561527:0.243190:0.561527:0.224669:0.184412:0.224669:0.015979:0.008550:0.004773:0.005105:0.008965:0.010625:0.008259:0.010542:0.008176:0.005043:0.008218:0.006973:0.004088:0.003735:0.009629:0.008176:0.004856:0.004088:0.003735:0.010208:0.007180:0.008259:0.010563:0.006869:0.004524:0.004088:0.003735:0.017245:0.008280:0.010106:0.004088:0.003735:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.007178:0.008446:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
60.  Leighl, N. B. :@0.147059:0.263769:0.282731:0.263769:0.282731:0.245248:0.147059:0.245248:0.009483:0.009483:0.004088:0.003735:0.010563:0.010749:0.008218:0.005105:0.009025:0.010521:0.004524:0.004088:0.004233:0.014754:0.004088:0.004233:0.010957:0.004088:0.003735
et al.:@0.283212:0.263769:0.318842:0.263769:0.318842:0.245057:0.283212:0.245057:0.007346:0.005727:0.004316:0.009048:0.004607:0.004586
 Molecular testing for selection of patients with lung cancer for epidermal :@0.318846:0.263769:0.886152:0.263769:0.886152:0.245248:0.318846:0.245248:0.004233:0.017245:0.009940:0.004711:0.008280:0.008280:0.010500:0.004939:0.008259:0.007097:0.004233:0.005644:0.008218:0.006827:0.005852:0.005105:0.010417:0.008965:0.004233:0.005478:0.009857:0.007097:0.004233:0.007159:0.008135:0.004711:0.008280:0.008280:0.005852:0.005043:0.009857:0.010687:0.004233:0.009857:0.005644:0.004233:0.010334:0.008010:0.005852:0.005043:0.008218:0.010355:0.005852:0.006973:0.004233:0.013385:0.004792:0.006018:0.010417:0.004233:0.004462:0.010376:0.010417:0.008965:0.004233:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.004233:0.005478:0.009857:0.007097:0.004233:0.008301:0.010065:0.005043:0.010293:0.008218:0.007097:0.015979:0.008550:0.004773:0.003735
growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: Amer-:@0.184412:0.284348:0.882353:0.284348:0.882353:0.265827:0.184412:0.265827:0.008965:0.006765:0.009878:0.013385:0.006018:0.010417:0.005250:0.005644:0.008446:0.008280:0.005644:0.009857:0.007097:0.005250:0.006765:0.008280:0.008176:0.008301:0.010044:0.005644:0.009857:0.007097:0.005250:0.008259:0.010542:0.010355:0.005250:0.008261:0.010625:0.008010:0.010148:0.004939:0.008446:0.006827:0.005852:0.005043:0.008176:0.005250:0.004711:0.008840:0.015709:0.010148:0.010272:0.009857:0.015979:0.008446:0.005250:0.009733:0.005105:0.010625:0.008446:0.007159:0.008218:0.005250:0.005852:0.008840:0.006765:0.009961:0.006910:0.005105:0.010542:0.008218:0.005250:0.009733:0.005105:0.010625:0.008446:0.007159:0.008218:0.005250:0.005105:0.010791:0.010417:0.005043:0.009836:0.004794:0.005644:0.009857:0.006931:0.006973:0.004088:0.005250:0.013572:0.015896:0.008218:0.006661:0.006848
ican Society of Clinical Oncology endorsement of the College of American Pathologists/:@0.184412:0.304926:0.882415:0.304926:0.882415:0.286406:0.184412:0.286406:0.005043:0.008280:0.008259:0.010687:0.005893:0.009629:0.010251:0.008176:0.005043:0.008301:0.005852:0.008840:0.005893:0.009859:0.005644:0.005893:0.013406:0.004773:0.005105:0.010687:0.005041:0.008280:0.008550:0.004773:0.005893:0.014817:0.010542:0.008176:0.009940:0.004711:0.010044:0.009587:0.008840:0.005893:0.008218:0.010542:0.010293:0.009857:0.006931:0.007159:0.008218:0.015896:0.008218:0.010355:0.005852:0.005893:0.009857:0.005644:0.005893:0.006018:0.010272:0.008218:0.005893:0.013634:0.009940:0.004897:0.004711:0.008218:0.008778:0.008218:0.005893:0.009857:0.005644:0.005893:0.013572:0.015896:0.008218:0.007097:0.005043:0.008280:0.008259:0.010687:0.005893:0.010378:0.008010:0.006018:0.010272:0.009940:0.004711:0.010044:0.008965:0.005105:0.006827:0.005852:0.006973:0.006454
International Association for the study of lung cancer/association for molecular pathology :@0.184412:0.325505:0.886043:0.325505:0.886043:0.306984:0.184412:0.306984:0.006267:0.010355:0.005644:0.008218:0.007097:0.010625:0.008010:0.005852:0.005043:0.009857:0.010625:0.008550:0.004773:0.004731:0.013260:0.006848:0.007159:0.010251:0.008176:0.005271:0.008010:0.005852:0.005043:0.009857:0.010687:0.004731:0.005478:0.009857:0.007097:0.004731:0.006018:0.010272:0.008218:0.004731:0.006827:0.005603:0.010314:0.010293:0.008840:0.004731:0.009859:0.005644:0.004731:0.004462:0.010376:0.010417:0.008965:0.004731:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.006454:0.008446:0.006848:0.007157:0.010251:0.008176:0.005271:0.008010:0.005852:0.005043:0.009857:0.010687:0.004731:0.005478:0.009857:0.007097:0.004731:0.015896:0.009940:0.004711:0.008278:0.008280:0.010500:0.004939:0.008259:0.007097:0.004731:0.010334:0.008010:0.006018:0.010272:0.009940:0.004713:0.010044:0.009585:0.008840:0.003735
guideline. J. Clin. Oncol. 32, 3673–3679 (2014).:@0.184412:0.346084:0.545716:0.346084:0.545716:0.327563:0.184412:0.327563:0.008965:0.010376:0.005043:0.010293:0.008135:0.004773:0.005105:0.010542:0.007948:0.004088:0.003735:0.005105:0.004088:0.003735:0.013403:0.004773:0.005105:0.010687:0.004088:0.003735:0.014817:0.010542:0.008176:0.009940:0.004524:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
61.  Warren, J. D. :@0.147059:0.366663:0.284455:0.366663:0.284455:0.348142:0.147059:0.348142:0.009483:0.009483:0.004088:0.003735:0.010563:0.017079:0.008259:0.007097:0.006765:0.008218:0.010687:0.004088:0.003549:0.005105:0.004088:0.003549:0.013738:0.004088:0.003735
et al.:@0.284248:0.366663:0.319183:0.366663:0.319183:0.347951:0.284248:0.347951:0.007346:0.005727:0.003619:0.009050:0.004607:0.004586
 Septin 9 methylated DNA is a sensitive and specific blood test for colorec-:@0.319182:0.366663:0.882353:0.366663:0.882353:0.348142:0.319182:0.348142:0.003549:0.009629:0.008301:0.010044:0.005852:0.005105:0.010687:0.003549:0.009483:0.003549:0.015896:0.008301:0.006018:0.010065:0.008902:0.004939:0.008010:0.005644:0.008280:0.010355:0.003549:0.014339:0.014007:0.013572:0.003549:0.005105:0.006973:0.003549:0.008446:0.003549:0.007157:0.008218:0.010563:0.006910:0.004794:0.005852:0.005043:0.008757:0.008218:0.003549:0.008259:0.010542:0.010355:0.003549:0.006827:0.010459:0.008280:0.008176:0.005105:0.005167:0.005105:0.008176:0.003549:0.009917:0.004713:0.010249:0.010251:0.010355:0.003549:0.005644:0.008218:0.006827:0.005852:0.003549:0.005478:0.009857:0.007097:0.003549:0.008176:0.009940:0.004711:0.009857:0.006765:0.008280:0.008090:0.006848
tal cancer. BMC Med. 9, 133 (2011).:@0.184412:0.387241:0.458020:0.387241:0.458020:0.368720:0.184412:0.368720:0.005956:0.008550:0.004773:0.003735:0.008280:0.008259:0.010542:0.008176:0.008218:0.005686:0.004088:0.003735:0.011496:0.017450:0.013343:0.003735:0.017245:0.008280:0.010106:0.004088:0.003735:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
62.  Gormally, E. :@0.147059:0.407820:0.283937:0.407820:0.283937:0.389299:0.147059:0.389299:0.009483:0.009483:0.004088:0.003735:0.010563:0.014381:0.009857:0.007097:0.015979:0.008550:0.004897:0.004711:0.007263:0.004088:0.003881:0.010998:0.004088:0.003735
et al.:@0.284079:0.407820:0.319357:0.407820:0.319357:0.389108:0.284079:0.389108:0.007346:0.005727:0.003964:0.009048:0.004607:0.004586
 TP53 and KRAS2 mutations in plasma DNA of healthy subjects and sub-:@0.319358:0.407820:0.882353:0.407820:0.882353:0.389299:0.319358:0.389299:0.003881:0.012140:0.011061:0.009483:0.009483:0.003881:0.008259:0.010542:0.010355:0.003881:0.013219:0.012409:0.013696:0.009193:0.009483:0.003881:0.015709:0.010065:0.005956:0.008010:0.005852:0.005043:0.009857:0.010563:0.006973:0.003881:0.005105:0.010687:0.003881:0.010145:0.004939:0.008446:0.006910:0.015979:0.008446:0.003881:0.014339:0.014007:0.013572:0.003881:0.009857:0.005644:0.003881:0.010272:0.008446:0.008548:0.004462:0.006018:0.010065:0.008840:0.003881:0.006827:0.010314:0.009816:0.004854:0.008280:0.008280:0.005852:0.006973:0.003881:0.008259:0.010542:0.010355:0.003881:0.006827:0.010314:0.010012:0.006848
sequent cancer occurrence: a prospective study. Cancer Res. 66, 6871–6876 (2006).:@0.184412:0.428399:0.815693:0.428399:0.815693:0.409878:0.184412:0.409878:0.007159:0.008280:0.009733:0.010314:0.008218:0.010355:0.005852:0.003735:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.010249:0.008176:0.008280:0.010376:0.007097:0.006765:0.008218:0.010542:0.008176:0.008218:0.004088:0.003735:0.008446:0.003735:0.010065:0.006765:0.009961:0.006827:0.010459:0.008280:0.008280:0.005852:0.005043:0.008757:0.008218:0.003735:0.006827:0.005603:0.010314:0.010293:0.007263:0.004088:0.003735:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.012449:0.008218:0.006973:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
63.  Beaver, J. A. :@0.147059:0.448977:0.277213:0.448977:0.277213:0.430456:0.147059:0.430456:0.009483:0.009483:0.004088:0.003735:0.010563:0.011891:0.008446:0.008114:0.008757:0.008218:0.005686:0.004088:0.003507:0.005105:0.004088:0.003507:0.013572:0.004088:0.003735
et al.:@0.276963:0.448977:0.311846:0.448977:0.311846:0.430265:0.276963:0.430265:0.007346:0.005727:0.003569:0.009048:0.004607:0.004586
 Detection of cancer DNA in plasma of patients with early-stage breast can-:@0.311854:0.448977:0.882353:0.448977:0.882353:0.430456:0.311854:0.430456:0.003507:0.014754:0.008299:0.005644:0.008280:0.008280:0.005852:0.005043:0.009857:0.010687:0.003507:0.009857:0.005644:0.003507:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.003507:0.014339:0.014007:0.013572:0.003507:0.005105:0.010687:0.003507:0.010148:0.004939:0.008446:0.006910:0.015979:0.008446:0.003507:0.009857:0.005644:0.003507:0.010334:0.008010:0.005852:0.005043:0.008218:0.010355:0.005852:0.006973:0.003507:0.013385:0.004792:0.006018:0.010417:0.003507:0.008446:0.008259:0.006910:0.004711:0.008840:0.006848:0.006827:0.005956:0.008363:0.008778:0.008218:0.003507:0.009834:0.006767:0.008444:0.008446:0.006829:0.005852:0.003507:0.008280:0.008259:0.010604:0.006848
cer. Clin. Cancer Res. 20, 2643–2650 (2014).:@0.184412:0.469556:0.522972:0.469556:0.522972:0.451035:0.184412:0.451035:0.008176:0.008218:0.005686:0.004088:0.003735:0.013406:0.004773:0.005105:0.010687:0.004088:0.003735:0.013611:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.012451:0.008218:0.006973:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
64.  Dawson, S.-J. :@0.147059:0.490135:0.289963:0.490135:0.289963:0.471614:0.147059:0.471614:0.009483:0.009483:0.004088:0.003735:0.010563:0.014734:0.008114:0.013385:0.007159:0.009857:0.010687:0.004088:0.004472:0.009193:0.004088:0.006848:0.005103:0.004088:0.003735
et al.:@0.290700:0.490135:0.326580:0.490135:0.326580:0.471423:0.290700:0.471423:0.007346:0.005727:0.004565:0.009048:0.004607:0.004586
 Analysis of circulating tumor DNA to monitor metastatic breast cancer. :@0.326584:0.490135:0.886090:0.490135:0.886090:0.471614:0.326584:0.471614:0.004472:0.013572:0.010625:0.008550:0.004711:0.008840:0.006910:0.005105:0.006973:0.004472:0.009857:0.005644:0.004472:0.008176:0.005105:0.006765:0.008280:0.010500:0.004939:0.008010:0.005852:0.005105:0.010417:0.008965:0.004472:0.005603:0.010376:0.015896:0.009857:0.007097:0.004472:0.014339:0.014007:0.013572:0.004472:0.005644:0.010044:0.004472:0.015896:0.009857:0.010687:0.004794:0.005644:0.009857:0.007097:0.004472:0.015896:0.008301:0.005956:0.008446:0.006827:0.005956:0.008010:0.005852:0.005043:0.008176:0.004472:0.009836:0.006765:0.008444:0.008446:0.006829:0.005852:0.004472:0.008278:0.008261:0.010542:0.008176:0.008218:0.005686:0.004088:0.003735
N. Engl. J. Med. 368, 1199–1209 (2013).:@0.184412:0.510713:0.487404:0.510713:0.487404:0.492193:0.184412:0.492193:0.014754:0.004088:0.003735:0.010998:0.010417:0.009027:0.004524:0.004088:0.003735:0.005105:0.004088:0.003735:0.017243:0.008280:0.010106:0.004088:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
65.  Gray, E. S. :@0.147059:0.531292:0.264907:0.531292:0.264907:0.512771:0.147059:0.512771:0.009483:0.009483:0.004088:0.003735:0.010563:0.014070:0.007180:0.008114:0.007263:0.004088:0.003839:0.010998:0.004088:0.003839:0.009193:0.004088:0.003735
et al.:@0.264985:0.531292:0.300221:0.531292:0.300221:0.512580:0.264985:0.512580:0.007346:0.005727:0.003922:0.009048:0.004607:0.004586
 Circulating tumor DNA to monitor treatment response and detect acquired :@0.300213:0.531292:0.886154:0.531292:0.886154:0.512771:0.300213:0.512771:0.003839:0.013281:0.005105:0.006765:0.008280:0.010500:0.004939:0.008008:0.005852:0.005105:0.010417:0.008965:0.003839:0.005603:0.010376:0.015896:0.009857:0.007097:0.003839:0.014339:0.014007:0.013572:0.003839:0.005644:0.010044:0.003839:0.015896:0.009857:0.010687:0.004794:0.005644:0.009857:0.007097:0.003829:0.005852:0.006765:0.008446:0.008010:0.005852:0.015896:0.008218:0.010355:0.005852:0.003839:0.006765:0.008218:0.006827:0.010459:0.009857:0.010563:0.007159:0.008218:0.003839:0.008259:0.010542:0.010355:0.003829:0.010295:0.008299:0.005647:0.008278:0.008280:0.005852:0.003839:0.008446:0.008176:0.009733:0.010376:0.005105:0.006765:0.008280:0.010355:0.003735
resistance in patients with metastatic melanoma. Oncotarget 6, 42008–42018 (2015).:@0.184412:0.551871:0.829868:0.551871:0.829868:0.533350:0.184412:0.533350:0.006765:0.008218:0.006910:0.005105:0.006827:0.005956:0.008259:0.010542:0.008176:0.008218:0.003735:0.005105:0.010687:0.003735:0.010334:0.008010:0.005852:0.005043:0.008218:0.010355:0.005852:0.006973:0.003735:0.013385:0.004792:0.006018:0.010417:0.003735:0.015896:0.008301:0.005956:0.008446:0.006827:0.005956:0.008010:0.005852:0.005043:0.008176:0.003735:0.015896:0.008135:0.004939:0.008259:0.010542:0.009857:0.015979:0.008446:0.004088:0.003735:0.014817:0.010542:0.008176:0.009836:0.005956:0.008259:0.006931:0.008778:0.008301:0.005852:0.003735:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
66.  Tie, J. :@0.147059:0.572450:0.230958:0.572450:0.230958:0.553929:0.147059:0.553929:0.009483:0.009483:0.004088:0.003735:0.010563:0.011579:0.005043:0.007948:0.004088:0.004960:0.005105:0.004088:0.003735
et al.:@0.232166:0.572450:0.268544:0.572450:0.268544:0.553738:0.232166:0.553738:0.007346:0.005727:0.005063:0.009048:0.004607:0.004586
 Circulating tumor DNA analysis detects minimal residual disease and predicts :@0.268541:0.572450:0.886169:0.572450:0.886169:0.553929:0.268541:0.553929:0.004960:0.013281:0.005105:0.006765:0.008280:0.010500:0.004939:0.008010:0.005852:0.005105:0.010417:0.008965:0.004960:0.005603:0.010376:0.015896:0.009857:0.007097:0.004960:0.014339:0.014007:0.013572:0.004960:0.008259:0.010625:0.008550:0.004711:0.008840:0.006910:0.005105:0.006973:0.004960:0.010293:0.008301:0.005644:0.008280:0.008280:0.005852:0.006973:0.004960:0.016041:0.005105:0.010687:0.005105:0.015979:0.008550:0.004773:0.004960:0.006765:0.008218:0.006910:0.005043:0.010044:0.010542:0.008550:0.004773:0.004960:0.010355:0.005105:0.007157:0.008446:0.008446:0.007159:0.008218:0.004960:0.008259:0.010542:0.010355:0.004960:0.010065:0.006765:0.008280:0.010355:0.005043:0.008280:0.005852:0.006973:0.003735
recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346ra92 (2016).:@0.184412:0.593028:0.824095:0.593028:0.824095:0.574507:0.184412:0.574507:0.006765:0.008280:0.008280:0.010376:0.007097:0.006765:0.008218:0.010542:0.008176:0.008218:0.003735:0.005105:0.010687:0.003735:0.010332:0.008010:0.005852:0.005043:0.008218:0.010355:0.005852:0.006973:0.003735:0.013385:0.004794:0.006018:0.010417:0.003735:0.006827:0.005956:0.008363:0.008778:0.008218:0.003735:0.006599:0.006599:0.003735:0.008176:0.009938:0.004713:0.009857:0.010687:0.003735:0.008278:0.008261:0.010542:0.008176:0.008218:0.005686:0.004088:0.003735:0.009627:0.008176:0.004856:0.004088:0.003735:0.010210:0.007180:0.008259:0.010563:0.006869:0.004524:0.004088:0.003735:0.017245:0.008280:0.010106:0.004088:0.003735:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.007178:0.008446:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
67.  Garcia-Murillas, I. :@0.147059:0.613607:0.329277:0.613607:0.329277:0.595086:0.147059:0.595086:0.009483:0.009483:0.004088:0.003735:0.010563:0.014360:0.008259:0.006765:0.008176:0.005271:0.008446:0.006848:0.016954:0.010376:0.007097:0.005227:0.004897:0.004939:0.008446:0.006973:0.004088:0.003320:0.006599:0.004088:0.003735
et al.:@0.328848:0.613607:0.363545:0.613607:0.363545:0.594895:0.328848:0.594895:0.007346:0.005727:0.003383:0.009048:0.004607:0.004586
 Mutation tracking in circulating tumor DNA predicts relapse in ear-:@0.363549:0.613607:0.882353:0.613607:0.882353:0.595086:0.363549:0.595086:0.003320:0.016954:0.010065:0.005956:0.008010:0.005852:0.005043:0.009857:0.010687:0.003320:0.005852:0.007178:0.008446:0.007971:0.009730:0.005105:0.010417:0.008965:0.003320:0.005105:0.010687:0.003320:0.008176:0.005105:0.006765:0.008280:0.010500:0.004939:0.008010:0.005852:0.005105:0.010417:0.008965:0.003320:0.005603:0.010376:0.015898:0.009857:0.007097:0.003320:0.014339:0.014007:0.013572:0.003320:0.010065:0.006765:0.008280:0.010355:0.005043:0.008280:0.005852:0.006973:0.003320:0.006765:0.008135:0.004939:0.008010:0.010166:0.007159:0.008218:0.003320:0.005105:0.010687:0.003320:0.008446:0.008259:0.006511:0.006848
ly breast cancer. Sci. Transl. Med. 7, 302ra133 (2015).:@0.184412:0.634186:0.586159:0.634186:0.586159:0.615665:0.184412:0.615665:0.004711:0.008840:0.003735:0.009836:0.006765:0.008446:0.008446:0.006827:0.005852:0.003735:0.008280:0.008259:0.010542:0.008176:0.008218:0.005686:0.004088:0.003735:0.009629:0.008176:0.004854:0.004088:0.003735:0.010210:0.007180:0.008259:0.010563:0.006871:0.004522:0.004088:0.003735:0.017245:0.008280:0.010106:0.004088:0.003735:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.007178:0.008446:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
68.  Reinert, T. :@0.147059:0.654764:0.268788:0.654764:0.268788:0.636244:0.147059:0.636244:0.009483:0.009483:0.004088:0.003735:0.010563:0.012451:0.008218:0.005105:0.010542:0.008218:0.007242:0.005852:0.004088:0.004877:0.009961:0.004088:0.003735
et al.:@0.269932:0.654764:0.306226:0.654764:0.306226:0.636052:0.269932:0.636052:0.007346:0.005727:0.004980:0.009048:0.004607:0.004586
 Analysis of circulating tumour DNA to monitor disease burden following :@0.306232:0.654764:0.886069:0.654764:0.886069:0.636244:0.306232:0.636244:0.004877:0.013572:0.010625:0.008550:0.004711:0.008840:0.006910:0.005105:0.006973:0.004877:0.009857:0.005644:0.004877:0.008176:0.005105:0.006763:0.008280:0.010500:0.004939:0.008010:0.005852:0.005105:0.010417:0.008965:0.004877:0.005603:0.010376:0.015896:0.009836:0.010376:0.007097:0.004877:0.014339:0.014007:0.013572:0.004877:0.005644:0.010044:0.004877:0.015896:0.009857:0.010687:0.004794:0.005644:0.009857:0.007097:0.004877:0.010355:0.005105:0.007157:0.008446:0.008446:0.007159:0.008218:0.004877:0.009816:0.010376:0.006765:0.010293:0.008218:0.010687:0.004877:0.005478:0.009940:0.004897:0.004711:0.009878:0.013385:0.005105:0.010417:0.008965:0.003735
colorectal cancer surgery. Gut 65, 625–634 (2016).:@0.184412:0.675343:0.567920:0.675343:0.567920:0.656822:0.184412:0.656822:0.008176:0.009940:0.004711:0.009857:0.006765:0.008280:0.008280:0.005956:0.008550:0.004773:0.003735:0.008278:0.008259:0.010544:0.008176:0.008218:0.007097:0.003735:0.006825:0.010376:0.006931:0.008780:0.008218:0.007635:0.007263:0.004088:0.003735:0.013883:0.010065:0.005852:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
69.  Olsson, E. :@0.147059:0.695922:0.265177:0.695922:0.265177:0.677401:0.147059:0.677401:0.009483:0.009483:0.004088:0.003735:0.010563:0.014754:0.004773:0.006848:0.007159:0.009857:0.010687:0.004088:0.003777:0.010998:0.004088:0.003735
et al.:@0.265219:0.695922:0.300393:0.695922:0.300393:0.677210:0.265219:0.677210:0.007346:0.005727:0.003860:0.009048:0.004607:0.004586
 Serial monitoring of circulating tumor DNA in patients with primary breast :@0.300393:0.695922:0.886083:0.695922:0.886083:0.677401:0.300393:0.677401:0.003777:0.009629:0.008218:0.007097:0.005271:0.008550:0.004773:0.003777:0.015896:0.009857:0.010687:0.004794:0.005644:0.009857:0.007097:0.005105:0.010417:0.008965:0.003777:0.009857:0.005644:0.003777:0.008176:0.005105:0.006765:0.008280:0.010500:0.004939:0.008010:0.005852:0.005105:0.010417:0.008965:0.003777:0.005603:0.010376:0.015896:0.009857:0.007097:0.003777:0.014339:0.014007:0.013572:0.003777:0.005105:0.010687:0.003777:0.010332:0.008010:0.005852:0.005045:0.008218:0.010355:0.005852:0.006973:0.003777:0.013385:0.004792:0.006018:0.010417:0.003777:0.010065:0.007097:0.005105:0.015977:0.008261:0.007635:0.008840:0.003777:0.009836:0.006765:0.008444:0.008446:0.006829:0.005852:0.003735
cancer for detection of occult metastatic disease. EMBO Mol. Med. 7, 1034–1047 (2015).:@0.184412:0.716500:0.860597:0.716500:0.860597:0.697980:0.184412:0.697980:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.005478:0.009857:0.007097:0.003735:0.010293:0.008301:0.005644:0.008280:0.008280:0.005852:0.005041:0.009859:0.010687:0.003735:0.009855:0.005644:0.003735:0.010251:0.008176:0.008280:0.010500:0.004462:0.005852:0.003735:0.015896:0.008301:0.005956:0.008446:0.006827:0.005956:0.008010:0.005852:0.005043:0.008176:0.003735:0.010355:0.005105:0.007157:0.008446:0.008446:0.007159:0.007948:0.004088:0.003735:0.010998:0.017826:0.011868:0.014920:0.003735:0.017245:0.009940:0.004524:0.004088:0.003735:0.017245:0.008280:0.010106:0.004088:0.003735:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
70.  Martincorena, I. :@0.147059:0.737079:0.313196:0.737079:0.313196:0.718558:0.147059:0.718558:0.009483:0.009483:0.004088:0.003735:0.010563:0.017348:0.008259:0.007242:0.005852:0.005105:0.010542:0.008176:0.009857:0.006765:0.008218:0.010625:0.008446:0.004088:0.003839:0.006599:0.004088:0.003735
et al.:@0.313303:0.737079:0.348540:0.737079:0.348540:0.718367:0.313303:0.718367:0.007346:0.005727:0.003922:0.009048:0.004607:0.004586
 Tumor evolution. High burden and pervasive positive selection of so-:@0.348543:0.737079:0.882353:0.737079:0.882353:0.718558:0.348543:0.718558:0.003839:0.009919:0.010376:0.015896:0.009857:0.007097:0.003839:0.008487:0.008757:0.009940:0.004462:0.010065:0.005852:0.005043:0.009857:0.010687:0.004088:0.003839:0.014983:0.005105:0.009025:0.010417:0.003839:0.009816:0.010376:0.006765:0.010293:0.008218:0.010687:0.003839:0.008259:0.010542:0.010355:0.003839:0.010459:0.008218:0.007635:0.008944:0.008446:0.006910:0.005045:0.008757:0.008218:0.003839:0.010457:0.009961:0.006910:0.004794:0.005852:0.005043:0.008757:0.008218:0.003839:0.007159:0.008135:0.004711:0.008280:0.008280:0.005852:0.005043:0.009857:0.010687:0.003839:0.009857:0.005644:0.003839:0.007159:0.010064:0.006848
matic mutations in normal human skin. Science 348, 880–886 (2015).:@0.184412:0.757658:0.716377:0.757658:0.716377:0.739137:0.184412:0.739137:0.015979:0.008010:0.005852:0.005043:0.008176:0.003735:0.015709:0.010065:0.005956:0.008010:0.005852:0.005043:0.009857:0.010563:0.006973:0.003735:0.005105:0.010687:0.003735:0.010542:0.009857:0.007097:0.015979:0.008550:0.004773:0.003735:0.010085:0.010376:0.015979:0.008259:0.010687:0.003735:0.006869:0.009733:0.005105:0.010687:0.004088:0.003735:0.009627:0.008176:0.005043:0.008218:0.010542:0.008176:0.008218:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
71.  Martincorena, I. :@0.147059:0.778237:0.313954:0.778237:0.313954:0.759716:0.147059:0.759716:0.009483:0.009483:0.004088:0.003735:0.010563:0.017348:0.008259:0.007242:0.005852:0.005105:0.010542:0.008176:0.009857:0.006765:0.008218:0.010625:0.008446:0.004088:0.004596:0.006599:0.004088:0.003735
et al.:@0.314814:0.778237:0.350818:0.778237:0.350818:0.759525:0.314814:0.759525:0.007346:0.005727:0.004690:0.009048:0.004607:0.004586
 Somatic mutant clones colonize the human esophagus with age. Sci-:@0.350825:0.778237:0.882353:0.778237:0.882353:0.759716:0.350825:0.759716:0.004596:0.009629:0.009857:0.015979:0.008010:0.005852:0.005043:0.008176:0.004594:0.015709:0.010065:0.005956:0.008261:0.010355:0.005852:0.004594:0.007969:0.004711:0.009857:0.010544:0.008218:0.006973:0.004594:0.008176:0.009940:0.004711:0.009857:0.010687:0.005105:0.008031:0.008218:0.004596:0.006018:0.010272:0.008218:0.004596:0.010085:0.010376:0.015979:0.008259:0.010687:0.004596:0.008218:0.007157:0.009836:0.010148:0.010355:0.008365:0.008965:0.010376:0.006973:0.004594:0.013385:0.004794:0.006018:0.010417:0.004596:0.008363:0.008778:0.007948:0.004088:0.004594:0.009629:0.008176:0.005107:0.006848
ence 362, 911–917 (2018).:@0.184412:0.798815:0.385578:0.798815:0.385578:0.780294:0.184412:0.780294:0.008218:0.010542:0.008176:0.008218:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
72.  Vaughan, S. :@0.147059:0.819394:0.279662:0.819394:0.279662:0.800873:0.147059:0.800873:0.009483:0.009483:0.004088:0.003735:0.010563:0.011704:0.008010:0.010376:0.009027:0.010355:0.008259:0.010687:0.004088:0.005727:0.009193:0.004088:0.003735
et al.:@0.281666:0.819394:0.318841:0.819394:0.318841:0.800682:0.281666:0.800682:0.007346:0.005727:0.005860:0.009048:0.004607:0.004586
 Rethinking ovarian cancer: recommendations for improving outcomes. :@0.318841:0.819394:0.886045:0.819394:0.886045:0.800873:0.318841:0.800873:0.005727:0.012451:0.008301:0.006018:0.010417:0.005105:0.010791:0.009733:0.005105:0.010417:0.008965:0.005727:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.005727:0.008280:0.008259:0.010542:0.008176:0.008218:0.007388:0.004088:0.005727:0.006765:0.008280:0.008176:0.009857:0.016041:0.015896:0.008218:0.010542:0.010521:0.008010:0.005852:0.005043:0.009857:0.010563:0.006973:0.005727:0.005478:0.009857:0.007097:0.005727:0.005105:0.015709:0.010065:0.006765:0.009878:0.008944:0.005105:0.010417:0.008965:0.005727:0.009836:0.010065:0.005644:0.008176:0.009857:0.015896:0.008218:0.006973:0.004088:0.003735
Nat. Rev. Cancer 11, 719–725 (2011).:@0.184412:0.839973:0.468792:0.839973:0.468792:0.821452:0.184412:0.821452:0.014132:0.008010:0.005852:0.004088:0.003735:0.012451:0.008487:0.007367:0.004088:0.003735:0.013611:0.008259:0.010544:0.008176:0.008218:0.007097:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
73.  Bowtell, D. D. :@0.147059:0.860551:0.292756:0.860551:0.292756:0.842031:0.147059:0.842031:0.009483:0.009483:0.004088:0.003735:0.010563:0.011891:0.009878:0.013385:0.005644:0.008135:0.004897:0.004524:0.004088:0.003258:0.013738:0.004088:0.003258:0.013738:0.004088:0.003735
et al.:@0.292277:0.860551:0.326921:0.860551:0.326921:0.841839:0.292277:0.841839:0.007346:0.005727:0.003331:0.009048:0.004607:0.004586
 Rethinking ovarian cancer II: reducing mortality from high-grade serous :@0.326920:0.860551:0.886089:0.860551:0.886089:0.842031:0.326920:0.842031:0.003258:0.012451:0.008301:0.006018:0.010417:0.005105:0.010789:0.009733:0.005105:0.010417:0.008965:0.003258:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.003258:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.003258:0.006599:0.006599:0.004088:0.003258:0.006765:0.008280:0.010042:0.010316:0.008176:0.005105:0.010417:0.008965:0.003258:0.015898:0.009857:0.007240:0.005956:0.008550:0.004773:0.004794:0.005852:0.008840:0.003258:0.005831:0.006765:0.009857:0.016041:0.003258:0.010417:0.005105:0.009025:0.010417:0.006848:0.008965:0.007180:0.008446:0.010293:0.008218:0.003258:0.007159:0.008218:0.006765:0.009836:0.010376:0.006973:0.003735
ovarian cancer. Nat. Rev. Cancer 15, 668–679 (2015).:@0.184412:0.881130:0.587904:0.881130:0.587904:0.862609:0.184412:0.862609:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.003735:0.008280:0.008259:0.010542:0.008176:0.008218:0.005686:0.004088:0.003735:0.014132:0.008010:0.005852:0.004088:0.003735:0.012451:0.008485:0.007367:0.004088:0.003735:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
74.  Karnezis, A. N., Cho, K. R., Gilks, C. B., Pearce, C. L. & Huntsman, D. G. The disparate ori-:@0.147059:0.901709:0.882353:0.901709:0.882353:0.883188:0.147059:0.883188:0.009483:0.009483:0.004088:0.003735:0.010563:0.012866:0.008259:0.007097:0.010542:0.008487:0.008031:0.005105:0.006973:0.004088:0.004358:0.013572:0.004088:0.004358:0.014754:0.004088:0.004088:0.004358:0.013406:0.010272:0.009338:0.004088:0.004358:0.013219:0.004088:0.004358:0.012451:0.004088:0.004088:0.004358:0.014070:0.005229:0.004897:0.009566:0.006973:0.004088:0.004358:0.013343:0.004088:0.004358:0.010957:0.004088:0.004088:0.004358:0.010148:0.008446:0.008259:0.006765:0.008176:0.007948:0.004088:0.004358:0.013343:0.004088:0.004358:0.010563:0.004088:0.004358:0.014298:0.004358:0.014402:0.010376:0.010355:0.005852:0.006910:0.015979:0.008259:0.010687:0.004088:0.004358:0.013738:0.004088:0.004358:0.014256:0.004088:0.004358:0.010428:0.010282:0.008218:0.004358:0.010355:0.005105:0.006827:0.010334:0.008259:0.007178:0.008012:0.005644:0.008218:0.004358:0.009857:0.007097:0.005086:0.006848